Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed director
Landos Biopharma, Inc. (LABP) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/09/2023 8-K Quarterly results
Docs: "Landos Biopharma Provides Business Update & Reports Second Quarter 2023 Results Initiated NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis NEXUS Remains On Track With Top-line Results Planned for Q4 2024 Sufficient Cash to Fund Planned Operations into First Half of 2025 NEW YORK, August 9, 2023 –– Landos Biopharma, Inc. , a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today provided a business update and announced financial results for the second quarter ended June 30, 2023. “We continued to advance and execute the NX-13 Phase 2 clinical program during the second quarter. We have activated sites in the US and are actively recruiting and screening patients,” said Gregory Oakes, President and CEO of..."
05/12/2023 8-K Quarterly results
Docs: "Landos Biopharma Provides Business Update and Reports First Quarter 2023 Results NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis Initiated NEXUS Top-line Results Planned for Q4 2024 Sufficient Cash to Fund Planned Operations into First Half of 2025 NEW YORK, May 12, 2023 –– Landos Biopharma, Inc. , a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today provided a business update and announced financial results for the first quarter ended March 31, 2023. “We continue to execute on a focused strategy for the NX-13 program to maximize value for our shareholders,” said Gregory Oakes, President and CEO of Landos. “Our NEXUS Phase 2 study of NX-13 in UC is designed to advance this important progra...",
"LP 0/4 4/11 4/10 3/11"
03/23/2023 8-K Quarterly results
Docs: "Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2022 Results On Track to Initiate Phase 2 Proof-of-Concept Trial in Ulcerative Colitis for NX-13 in the Second Quarter of 2023 and Report Topline Results by the Fourth Quarter of 2024 Projected Cash Runway into First Half of 2025 NEW YORK, March 23, 2023 –– Landos Biopharma, Inc. , a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today provided a business update and announced financial results for the fourth quarter and full year ended December 31, 2022. “Meaningful progress has been made this year as we streamlined our product candidate portfolio to focus on our most promising asset. We believe Landos is uniquely positioned to transfor..."
11/10/2022 8-K Quarterly results
Docs: "Landos Biopharma Reports Third Quarter 2022 Results and Provides Business Update On Track to Complete Comprehensive Review of Clinical Development Plans in the Coming Weeks NEW YORK, November 10, 2022 –– Landos Biopharma, Inc. , a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced financial results for the third quarter ended September 30, 2022, and provided a business update. “Landos has made significant progress advancing our clinical-stage programs – omilancor, NX-13 and LABP-104,” said Gregory Oakes, President and CEO of Landos. “In August, we announced positive top-line results from our NX-13 Phase 1b trial, which showed a favorable safety and tolerability profile in ulcerative colitis p..."
08/11/2022 8-K Investor presentation, Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Landos Biopharma Reports Second Quarter 2022 Results and Provides Business Update",
"NX-13 Presentation"
05/12/2022 8-K Quarterly results
03/24/2022 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Landos Biopharma Reports Fourth Quarter and Full Year 2021 Results and Provides Business Update"
11/15/2021 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Landos Biopharma Reports Third Quarter 2021 Financial Results and Provides Corporate Update"
08/02/2021 8-K Quarterly results
Docs: "Landos Biopharma Reports Second Quarter 2021 Financial Results and Provides Business Updates"
05/17/2021 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy